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Abstract
Background: Recently, nanometer sized vesicles (termed exosomes) have been described as a
component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease.
Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study
was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients
undergoing standard therapy.
Methods: Ten patients (with locally advanced PCa) provided spot urine specimens at three time
points during standard therapy. Patients received 3–6 months neoadjuvant androgen deprivation
therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to
the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant
ADT according to clinical need. Exosomes were purified, and the phenotype compared to
exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors
was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present
in urine were quantified, and expression of prostate markers (PSA and PSMA) and tumour-
associated marker 5T4 was examined.
Results: The quantity and quality of exosomes present in urine was highly variable, even though
we handled all materials freshly and used methods optimized for obtaining highly pure exosomes.
There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this
was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa
specimens, and not detected in healthy donor specimens. There was a clear treatment-related
decrease in exosomal prostate markers in 1 (of 8) patient.
Conclusion: Evaluating urinary-exosomes remains difficult, given the variability of exosomes in
urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple
markers of malignancy that could provide clinically useful information.
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Prostate cancer (PCa) remains the most prevalent male
cancer in the west, with projected 186,000 new cases, and
28,000 deaths in the USA expected in 2008 (American
Cancer Society, Atlanta, Georgia 2008). Whilst advances
are being made in understanding the biology underlying
this disease, and in many respects in its treatment, there
remains a need for better tools for PCa diagnosis and
monitoring.
Disease-related biomarker(s) should ideally be non-inva-
sively available; urine-analysis fits this requirement well.
Several urine-borne molecules are currently being evalu-
ated as PCa-indicators [1-10], but recently, approaches
measuring several candidate urine-markers at once may
give a more complete clinical picture [11-13].
Nano-meter sized vesicles (termed exosomes) are an addi-
tional component of urine [14], which have been pro-
posed as a possible source of multiple biomarkers of renal
disease [14,15] in particular, but perhaps also of interest
in urological cancer. Exosomes are a notable feature of
malignancy, with elevated exosome secretion [16] and
tumour-antigen enrichment of exosomes associated with
cancer cells [17,18]. The physiological importance of can-
cer exosomes remains unclear. There are several studies
suggesting they may act as an advantageous source of mul-
tiple tumour rejection antigens for activating anti-cancer
immune responses [17-19]. Cancer exosomes have been
proposed by some as possible therapeutic vaccines [20].
Paradoxically, however, there is also a growing number of
reports demonstrating active immune-suppressive func-
tions for cancer exosomes, assisting cancers evade
immune attack [21-24]. Cancer exosomes may also con-
tribute to angiogenic processes [25], may disseminate
metastatic potential in certain settings [26] and could play
roles in drug resistance [27].
From a biomarker perspective, the expression of tumour-
associated antigens by exosomes naturally raises ques-
tions about the possible value of these nano-vesicles as
markers of malignancy. Furthermore, exosomes may be a
source of important cancer-associated antigens not availa-
ble as soluble molecules within biological fluids, such as
the oncofetal glycoprotein-5T4; which is over expressed
by epithelial cancers but not shed from the cell surface
[28]. Biological changes related to malignancy of the gen-
itourinary tract, or to therapy, may perhaps be mirrored
by changes in urinary exosomes.
In this report, we present a pilot study with the key aim of
evaluating the feasibility of studying urine exosomes of
PCa patients, as tools for monitoring response to treat-
ment. Whilst we have discovered some difficulties such as
variability and low quantity of urine-borne exosomes, the
study provides the first encouraging evidence suggesting
that further molecular analyses of urine exosomes in PCa
are warranted.
Methods
Prostate Cancer patients and healthy donors
Ten PCa patients, participating in a local Phase II Clinical
Trial, were recruited, together with 10 healthy male volun-
teers. The patients were confirmed positive for PCa by
biopsy, and the tumour stage, Gleason score, serum-PSA
and age is summarised in Table 1. Patients received 3–6
months neoadjuvant androgen deprivation therapy
(ADT) prior to radical radiotherapy (RT), which consisted
of a single phase delivering 55 Gy in 20 fractions to the
prostate and 44 Gy in 20 fractions to the pelvic nodes.
Patients were continued on adjuvant ADT according to
clinical need. The trial was approved by the South East
Wales Ethics Committee.
Urine sample collection
Urine, up to 200 ml volume, collected into sterile contain-
ers (Millipore), was brought to the laboratory for process-
ing within 30 minutes. Samples were collected mid to late
morning, and these were not first-morning urine. Urine
was tested for blood, proteins, glucose and Ketones and
the pH was measured; (by Combur5 Test®D, dipstick
(Roche)) (summarised in Table 2). PCa-patient urine was
collected at three time points: "ADT4" (0–4 weeks after
initiation of ADT), "ADT12" (following three months of
ADT) and "RT20" (after 20 fractions of Radiotherapy). At
intervals during treatment (ADT4, ADT12 and at 4 weeks
post Radiotherapy), serum PSA levels were measured.
Exosome purification
Urine was subjected to serial centrifugation, removing
cells (300 g, 10 min), removing non-cellular debris (2000
g, 15 min). The supernatant was then underlayed with a
30% sucrose/D2O cushion, and subjected to ultracentrif-
ugation at 100,000 g for 2 h as described [17,23,29]. The
cushion was collected, and exosomes washed in PBS. Exo-
some pellets were resuspended in 100–150 ul of PBS and
frozen at -80°C. The quantity of exosomes was deter-
mined by the micro BCA protein assay (Pierce/Thermo
Scientific).
Cell culture
LNCaP and DU145 prostate cancer cell lines (from
ATCC), were seeded into bioreactor flasks (from Integra),
and maintained at high density culture for exosome pro-
duction as described [30].
Electrophoresis and Immuno-blotting
Cell lysates were compared to exosomes by immuno-blot-
ting as described [31]. Primary monoclonal antibodies
included mouse anti-human PSA (a gift from Dr AtillaPage 2 of 13
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TSG101, anti-LAMP-1, anti-HSP90, anti-Calnexin, anti-
CD81 and anti-PSMA (from Santa Cruz Biotechnology),
anti GAPDH (from BioChain Institute, Inc), anti CD9
(from R&D systems). Anti-5T4 was a gift from Dr R Har-
rop (Oxford BioMedica UK Ltd). Goat polyclonal anti-
Tamm Horsfall Protein (THP) was from Santa Cruz, and
bands were detected using anti-goat-HRP (Dako). Mem-
branes were stripped using the Restore Plus™ western blot-
ting stripping buffer (Pierce/Thermo Scientific), blocked
overnight, and re-probed.
Examining exosome membrane integrity
To investigate if urine damages exosome-membranes,
exosomes isolated from B-cell lines, were immobilised
onto anti-MHC Class-II coated dynal-beads (Dynal/Invit-
rogen) [32]. The exosome-bead complexes incubated
overnight at 37°C in 25 mM Calcein-AM as described
[31]. Calcein-loaded exosome-bead complexes were
exposed to various salt-solutions or to fresh urine, at room
temperature for 1 h. Fluorescence was analysed by flow
cytometry (FACScan, BD), running Cell Quest software
(BD). Calcein-fluorescence was compared to fluorescence
of anti-Class-I (RPE) stained exosome-beads, in parallel
tubes; a measure of whether exosomes remain attached to
the bead surface. Results are expressed as the ratio of Cal-
cein: Class-I fluorescence.
Examining proteolytic damage of exosomes by urine
Exosomes purified from LNCaP cells, were treated with
fresh urine in the presence or absence of protease inhibi-
tors (including EDTA, Pepstatin-A, Leupeptin and PMSF).
After 2 h or 18 h, samples were examined by western blot
for expression of CD9, PSA and TSG101. As a positive
control for proteolysis, exosomes were treated with
trypsin (Cambrex).
Results
Purification of urinary exosomes
We used a standardised method, designed for exosome-
purification from cell culture supernatant, and have
applied this to fresh-urine as an exosome source. With this
method, exosomes are isolated based on their buoyancy
characteristics [33]. Analysis of protein content of urine at
multiple steps throughout purification, revealed the
method was effective in eliminating principal contami-
nants (Fig 1a), (such as the band at 80 Kd) while signifi-
cantly concentrating vesicles bearing a distinct protein
repertoire, across the entire molecular weight spectrum
(Fig 1a). Performing immuno-blot analyses on parallel
gels revealed typical exosomal proteins were only detected
in the final exosome-product (Fig 1b).
Comparing this method with the method of Pisitkun et al
[14], using cell culture supernatants (Fig 1c) or healthy
donor urine (Fig 1d) as source material, showed the
Table 1: Details of patients participating in this study
Patient Clinical Stage
(all N0)
Gleason Score Age
(years)
Serum PSA
ADT4
(ng/ml)
Serum PSA
ADT12
(ng/ml)
Serum PSA
at 6 months
(ng/ml)
1 T2b 7 (3+4) 66 10.5 2.10 1.2
2 T2b 7 (3+4) 62 134.0 0.20 <0.01
3 T2 8 (3+5) 70 8.3 1.40 <0.1
4† n/d 7 (3+4) 65 83.2 83.40 †
5 T2c 7 (3+4) 69 95.2 4.10 <0.1
6 T2 8 (4+4) 70 10.8 0.10 <0.1
7 T3a 7 (3+4) 53 36.5 7.20 0.3
8 T3b 6 (3+3) 61 14.1 0.80 0
9 T2 7 (4+3) 66 21.1 0.20 <0.1
10 T2 8 (4+4) 71 28.1 1.3 n/d
† Patient died from an unrelated brain tumour prior to Radiation Treatment.
n/d not determined.Page 3 of 13
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in exosomes, evident by strong band intensity for exo-
some markers such as CD9, TSG101 and LAMP-1. Impor-
tantly, the sucrose method resulted in good enrichment of
tumour associated antigens; in this case 5T4 (Figure 1c),
indicating an important advantage in analysis of exo-
somes over pelleted sediment [14]. Although many mark-
ers were detected in the comparator preparation, these
were at a lower level. The more intense band for calnexin
(a non-exosomally expressed marker), is evidence for
more contaminants when using the comparator method
(Fig 1c). Similarly, with urine as the source material, the
sucrose-cushion method again proved advantageous (Fig
1d), showing higher levels of exosome expressed proteins,
and reduced contamination with Tamm Horfsall protein
(THP). The data support this approach for enriching exo-
somes from fresh urine specimens; and confers some
advantages over previously published urine-exosome pro-
tocols.
Table 2: Details of urine specimens collected from PCa patients
Patient Time Point Dip-Stick
Blood, Protein, Glucose, Ketones, pH
Specimen Volume
(ml)
Total Exosomes 
Recovered
(μg)
Exosome 
Concentration
(ng/ml)
1 ADT4 1 1 0 0 7 90 72.9 810.0
ADT12 0 1 0 0 5 180 141.9 788.3
RT20 0 0 0 0 7 180 19.6 109.3
2 ADT4 1 1 0 0 - 170 125.5 738.2
ADT12 1 2 0 0 7 180 2.61 14.5
RT20 0 0 0 0 5 90 39.2 435.7
3 ADT4 4 2 4 0 5 180 72.9 405.3
ADT12 2 1 1 0 5 180 70.9 393.9
RT20 0 1 1 0 5 60 8 133.3
4† ADT4 0 1 0 0 5 95 25.4 268.0
ADT12 1 3 3 0 5 55 6.54 118.9
RT20 - - - - - - - -
5 ADT4 4 0 0 0 5 180 38.4 213.6
ADT12 1 2 0 0 7 90 27.1 301.2
RT20 1 1 0 0 6 150 5.1 34.5
6 ADT4 0 0 0 0 6 180 19.4 108.1
ADT12 1 0 0 0 5 180 6.2 34.7
RT20 1 1 0 0 5 120 9.1 76.1
7 ADT4 3 1 1 0 6 97 39 402.1
ADT12 0 1 0 0 5 120 12.1 101.0
RT20 1 1 0 0 5 45 17.7 395.1
8 ADT4 0 1 1 0 6 150 125.1 834.4
ADT12 0 1 0 0 5 110 26 236.4
RT20 1 3 0 0 7 60 34.4 574.0
9 ADT4 0 1 0 0 5 120 8.2 68.3
ADT12 0 1 0 0 6 180 17 94.4
RT20 2 3 4 0 6 60 133.1 2218.7
10 ADT4 0 1 0 0 5 120 19.4 162.3
ADT12 0 0 0 0 7 180 11.4 63.4
RT20 0 0 0 0 6 170 88.3 519.4
† Patient 4 died before RT
- Not recorded, or sample unavailablePage 4 of 13
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The quantity of exosomes present in each preparation was
measured, corrected for starting urine volume, and values
compared across the patient (Table 2) and healthy donor
(Table 3) groups are summarised in figure 2. Prostate can-
cer patients on average had 1.2-fold higher levels of uri-
nary exosomes (at ADT4) compared to healthy men. There
was broad variation in the exosome-content across both
the healthy donors (366.8 ± 92.56, n = 10 mean ± SE) and
patients (443.2 ± 109.7, n = 10, ADT4). After three months
of androgen deprivation therapy (ADT12) there was a ~2-
fold decrease in exosome levels (224.9 ± 82.7, n = 10),
with 8 out of 10 patients showing a decrease in exosome
quantity. In terms of radiation treatment (RT20, 499.6 ±
225.6, n = 9), there was no significant difference com-
pared to ADT4 or to ADT12, as 3 out of 9 patients demon-
strated a further decrease in exosome levels, whilst 6 out
of 9 had increasing urinary exosome levels. There was a
decrease in serum PSA levels in 9/10 patients, demonstrat-
ing that standard therapy was successful in tumour bulk
reduction.
In conclusion it is not possible to demonstrate a correla-
tion between locally advanced PCa with the quantity of
exosomes present in urine, and there is no correlation
between serum PSA and urinary-exosome levels. From the
current data set, there is some suggestion however, that at
ADT12 there is a decrease in the amount of exosomes
present.
Prostate Cancer cell lines produce typical exosomes, 
positive for prostate and cancer-associated antigens
Two prostate cancer cell lines were maintained in culture,
as a source of PCa-exosomes, and the expression of typical
exosome-markers (e.g. the tetraspanin CD9) and some
known markers of prostate (PSA and PSMA) were exam-
ined. The LNCaP cells (whole cell lysates) were directly
compared to LNCaP-exosomes by immuno-blot, reveal-
ing positive exosomal expression of PSA and PSMA. There
was also clear positive exosomal expression of 5T4 by
LNCaP-exosomes. Both PSA and 5T4 were particularly
enriched in exosomes, compared to the parent cell (Fig
3A). The DU145 cell line, which does not express PSA or
PSMA served as a control demonstrating specific staining.
Purification of urine-derived exosomesFigure 1
Purification of urine-derived exosomes. Healthy donor urine was subjected to exosome purification, and at each step, 10 
μl of sample was kept for electrophoretic analysis (4–20% gradient polyacrylamide gel, silver stained) (A), demonstrating effec-
tive removal of the principal non-exosomal protein bands such as that at ~80 Kd, and significant enrichment of diverse protein 
species in the final exosome product (A). Parallel gels were run for immuno-blot analyses, using antibodies against typical exo-
some proteins as indicated (B). Comparing the sucrose cushion method, with a simpler method of Pisitkun et al, where cell cul-
ture media (C) or fresh urine (D) were subject to centrifugation at 17,000 g followed by pelletting at 200,000 g. Exosomes 
(from sucrose method) and the 200,000 g pellet were normalised for protein differences, and 2.5 μg/well analysed by western 
blot for markers as indicated.
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concluded that exosomes isolated from PCa cells express
molecules typical of exosomes from other cellular sources
together with prostate markers and tumour-associated
antigen(s). This immuno-blot panel was considered suit-
able for analysis of urinary exosomes in following studies.
The phenotype of healthy donor urinary exosomes
We performed analyses of urinary-exosomes from healthy
donors (HD), and compared expression levels for these
molecules to those of LNCaP-derived exosomes. Markers
such as TSG101 and CD9 were detected in most HD-spec-
imens by western blot, albeit at low levels compared to
the LNCaP standard, suggesting that at least some exo-
somes were present in these specimens. There was consid-
erable variability in band intensity obtained across these
donors, even though analyses were all normalised for dif-
ferences in protein. Prostate markers (PSA and PSMA)
were not expressed in any healthy donor specimens, indi-
cating that few if any exosomes in healthy donor urine
arise from the prostate. The tumour antigen 5T4 was not
found in any of the HD specimens (Figure 4).
In conclusion, examining urinary-exosomes obtained
from different donors by this method is certainly feasible,
and this is sufficient to reveal variation in exosome-qual-
ity across the samples. Nevertheless, in cases where exo-
some-quality was moderate/good (i.e. comparable to
LNCaP exosomes), healthy donor urinary-exosomes
could be confirmed negative for PSA, PSMA and 5T4.
Phenotype of PCa-patient's urinary exosomes, and 
evaluating changes with treatment
PCa patient derived exosomes were examined in a similar
manner. The data from 8 individual patients are shown
(Fig 5). Overall there was variability in band intensity
(with multiple markers) across the sample series, with
weak staining in most occasions compared to the LNCaP-
exosomes, yet there was some positivity for exosome-
markers in 20 of 24 samples. There was variation across
the patient cohort, and variation from within an individ-
ual's sample series (ADT4, ADT12 and RT20). As great atten-
tion was paid towards loading 5 μg of sample per well, we
believe the results more likely reflect the variable exo-
somal content of the sample, rather than technical issues
of sample loading. Bands for prostate-derived proteins
PSA or PSMA were evident in 5 patients (p1, p7, p8, p9,
p10), indicating that at least some of the exosomes
present in the urine were of prostate origin. Given the var-
iation in band intensity across the three time points in
most of these samples it is not possible to demonstrate
phenotypic changes in response to treatment. The excep-
tion to this is shown by patient 8, in which band intensi-
ties for exosome-markers were stable at all three time
points. This patient demonstrated a strong band for PSA
at ADT4, which diminished with treatment, becoming
undetectable at RT20. The band for PSMA also followed
this pattern to an extent, whilst the tumour-antigen 5T4
remained detectable at RT20, suggesting that there may be
some element of residual disease present, and that exo-
somal 5T4 may reflect this. The data are summarised in
Table 4.
Urine does not osmotically damage exosome membrane 
integrity
Our study highlighted variable quantity of exosomes in
urine specimens. This was ~10-times lower than expected,
according to others [34]. We hypothesised that variable
hydration state of individuals providing urine specimens
may lead to some differences in water/salt content of
urine; and that this may damage exosomes present in
urine. This would impact on exosome-flotation character-
Quantification of urine-derived exosomes, in healthy donors, and Prostate Cancer pati ntsFigure 2
Quantification of urine-derived exosomes, in healthy 
donors, and Prostate Cancer patients. The quantity of 
exosomes present in each preparation was measured using 
the BCA protein assay. Values were corrected for urine-
specimen volume, and are represented as ng Exosomes per 
ml of urine. Preparations from 10 healthy donors and 10 PCa 
patients undergoing standard therapy, at ADT4 (after 4 
weeks ADT), ADT12 (after 3 months of ADT), and at RT20 
(and after 20-fractions of radiotherapy) are compared. Bars 
represent mean+SE. *p < 0.5 using the Wilcoxon matched 
pairs test are shown.
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observed using the sucrose-cushion method.
Experiments were performed, using exosomes loaded
with a fluorescent dye, to assess how various osmotic con-
ditions might damage exosome membranes; revealing
that exosomes are surprisingly resistant to high and low
salt solutions (Figure 6a). Incubating exosomes in urine
specimens had no impact on the integrity of the mem-
brane (Figure 6b). We conclude that urine does not
osmotically damage the exosome membrane, and this is
unlikely to impact on the buoyancy characteristics of exo-
somes.
Exosomes are not prone to proteolysis by urine
Proteolytic damage of exosomal constituents, by urine-
proteases, may also explain low exosome levels we
observed. Unlike Pisitkun et al, we used fresh urine speci-
mens without protease inhibitors. To test this, we purified
exosomes from LNCaP cultures, and incubated these with
urine specimens in the presence/absence of protease
inhibitors. Analysis of exosome markers by western blot
revealed fresh urine specimens did not cause degradation
of exosome-markers tested. We conclude that exosomes
can largely resist endogenous proteolytic activity of urine
(for at least 18 hours at 37°C) (Figure 6c).
Discussion
We present the findings of a pilot study, investigating uri-
nary exosomes in prostate cancer patients. We had two
main aims in the study; firstly to assess the feasibility of
using urine as an exosome source in the context of a clin-
ical trial, and secondly to demonstrate changes occurring
in response to standard PCa-therapy. We anticipated
being able to show differences in urinary exosome quan-
tity, between healthy individuals, and individuals with
Table 3: Details of urine specimens collected from healthy donors
Healthy Donor Age of donor Dip-Stick
Blood, Protein, Glucose, Ketones, pH
Specimen Volume
(ml)
Exosomes 
Recovered
(μg)
Exosome 
Concentration
(ng/ml)
1 29 0 0 0 0 7 180 9.8 54.4
2 37 0 1 0 0 7 180 115.2 640.0
3 37 0 1 0 0 7 180 32.3 179.4
4 63 2 0 0 0 5 180 55.4 307.8
5 61 0 1 0 0 7 180 154.7 859.4
6 50 0 1 0 0 7 180 8.7 48.3
7 49 0 0 0 0 6 150 61.2 408.0
8 55 0 1 0 0 6 180 37.2 206.7
9 56 0 0 4 0 7 145 28.5 196.6
10 57 0 1 0 0 8 170 130.3 766.5
Characterising exosomes produced by LNCaP-prostate can-cer cell lineFigure 3
Characterising exosomes produced by LNCaP-pros-
tate cancer cell line. Prostate cancer cell lines (LNCaP and 
DU145), as indicated, were maintained in culture as a source 
of positive-control prostate cancer exosomes (for subse-
quent analyses). Whole cell lysates (CL) or exosomes (Exo) 
were analysed by SDS-PAGE (5 μg/well), with a panel of anti-
bodies as indicated.
72Kd
33Kd
46kd
36kd
100Kd
CL     Exo CL     Exo
GAPDH
PSMA
5T4
TSG101
PSA
LNCaP DU145Page 7 of 13
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ing exosomally expressed PCa-markers in response to
therapy.
Firstly, it is certainly feasible to collect spot urine speci-
mens (up to 200 ml) from PCa patients, at multiple time
points during standard treatment. The exosome purifica-
tion method is laborious however, with 30 samples occu-
pying 30-days of preparation time. This approach is not
suited to larger scale trials or screening programmes, but
was aimed at achieving the best quality preparations pos-
sible.
Our study highlights considerable variation in the quan-
tity of exosomes available from spot urine specimens, and
this was 10× lower than expected based on previous
reports [34], where exosomes were not isolated based
upon their buoyancy. Whilst some effort was invested in
accounting for this discrepancy, such as evaluating the
impact of urine protease activity on exosomes, or the
effect of osmotic conditions on exosome membrane
integrity, this discrepancy may simply be due to the pres-
ence of more non-exosomal contaminants present when
using a simple pelletting approach; and that exosomes are
therefore less abundant in urine than originally thought.
Comparing urinary-exosome quantity as we have done
here is unlikely to provide meaningful information to the
clinic, as there was no real difference between healthy
men and those with locally advanced disease. We did
observe a 2-fold decrease in urinary exosomes following
3-months ADT, where 8 of 10 patients showed a reduc-
tion in their urinary exosome content, and of these, 6 had
reductions of >50%. This lower exosome level was not
well maintained, with 5 of 9 patients showing elevated
exosome levels with radiotherapy. In contrast, serum PSA
levels demonstrated that all but one patient had
responded well to treatment, with levels below 1.5 ng/ml
at 6 months post treatment. There was no correlation
between this surrogate cancer-marker, and the quantity of
urinary exosomes. One may speculate that the reduction
in prostate volume caused by ADT may explain the
decrease in urinary-exosomes, and that radiation, a docu-
mented stimulus for exosome secretion [16], and a potent
inducer of a robust local inflammatory response, may ele-
vate exosomal urine content following radiotherapy.
These aspects require further investigation.
Measuring protein quantity (present in purified exosome
preparations), is clearly not sufficient to discriminate can-
cer cell derived exosomes, from a "high background" of
non-cancer cell exosomes present in this complex mixed
Characterising exosomes from healthy donor urineFigure 4
Characterising exosomes from healthy donor urine. Six healthy donors (detailed in Table 3), provided urine specimens 
and exosomes were purified. Western blots were performed with 5 μg urine-derived exosomes/well, or with 5 μg LNCaP-
derived exosomes (Exo) or 5 μg LNCaP whole cell lysates (CL). Blots were probed with antibodies against PSA, TSG101, 5T4, 
CD9 and GAPDH, as indicated.
36kd
CL   Exo
LNCaP
GAPDH
5T4
PSA
HD1  HD2  HD3                  HD4   HD5   HD6
72Kd
33Kd
TSG101 46kd
CD9 22Kd
PSMA 100Kd
Age of donor
29    37    37                63    61   50Page 8 of 13
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involve an immuno-affinity based method, for identifying
(and quantifying) the proportion of tumour marker posi-
tive exosomes present in urine. One group has previously
reported an approach, based upon EpCAM expression by
ovarian cancer derived exosomes, for analysing exosomes
present in the circulation [35]. We and likely others are
working to develop an ELISA-like approach, better suited
as a screening tool for cancer-derived exosomes in urine
and other body fluids. Knowledge from this study will
assist us in developing this tool.
In terms of exosome-phenotype, this study has high-
lighted some interesting observations from some of the
PCa patients' specimens. Firstly, it was not previously
known that the prostate can contribute any exosomes to
the total urine exosome-pool. In healthy donors there was
no positive staining for the prostate markers PSA or PSMA,
and the tumour marker 5T4 was also negative. In the
patient cohort, PSA was evident in 8/20, and PSMA
present in 9/20 specimens (where 20/24 specimens were
positive for one or more exosome-markers; i.e. evaluable
as exosome-positive). Staining for 5T4 showed positivity
in 14/20 samples. Together, this demonstrates for the first
time, expression of prostate and cancer-associated mark-
ers by urinary exosomes.
One particular patient (p8) demonstrated comparable
exosomes at each of the three time points, and a clear loss
of exosomal-PSA in response to therapy. Unexpectedly,
5T4 remained strongly expressed, even following 20-frac-
tions of radiotherapy, suggesting this may be a candidate
marker for assessing the presence of residual malignant
cells, refractory to the effects of androgen-ablation or radi-
otherapy. This aspect certainly warrants follow up studies,
Characterising exosomes from PCa patientsFigure 5
Characterising exosomes from PCa patients. Urinary exosomes (5 μg/well), isolated from 8 PCa patients (at ADT4, 
ADT12 or RT20), were subject to western blot analyses with a panel of antibodies as indicated. Whole cell lysates (CL) or exo-
somes (Exo) of LNCaP (5 μg/well) was included on each gel as positive controls.
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presence of treatment-resistant cells.
The future of urine-exosome analysis in prostate cancer
remains uncertain. This study has demonstrated that
extensive steps taken to freshly process and highly purify
exosomes from urine are labour intensive, yet results in a
variable product with only 17% of attempts containing
exosomes of comparable quality to those obtained from
cell culture. When the exosome content of source material
is consistent, variation due to the preparation method
used is <1% [30]. It may be possible to overcome this
degree of heterogeneity in the exosome content of the
source material, for example by 24 hr urine collection or
Table 4: Summary of patient's western blot data
Exosome Markers Cancer Marker Prostate Markers 
Patient Time CD9 GAPDH TSG101 5T4 PSMA PSA Summary
LNCap N/A ++++ +++ +++ +++ ++++ ++++ The Comparator "Standard" 
Sample
Good Quality p8 ADT4 +++ ++ ++ ++ ++ +++ Consistent, High Quality 
Exosomes.
ADT12 +++ ++ ++ ++ ++ + Prostate markers diminish 
with treatment.
RT20 +++ ++ ++ + - - 5T4 still evident at RT20
p7 ADT4 ++ + ++ + + + Good quality exosomes, but 
inconsistent, (increasing 
with treatment).
ADT12 ++ ++ +++ ++ + + Prostate markers & 5T4 still 
evident at RT20
RT20 +++ +++ +++ ++ ++ ++
Intermediate Quality p1 ADT4 + - - + - + Inconsistent, 
(increasing with treatment)
ADT12 ++ - - + - - Prostate markers barely 
detected, no clear pattern.
RT20 +++ + ++ + + - 5T4 still evident at RT20
p3 ADT4 + + - + - - Inconsistent, 
(increasing with treatment)
ADT12 + - ++ + - - Prostate markers absent.
RT20 +++ ++ - ++ - - Strong 5T4 at RT20
Poor p9 ADT4 +++ + + + + + Inconsistent, 
(decreasing with treatment)
ADT12 ++ + - - - - Prostate markers barely 
detected, no clear pattern.
RT20 + - - - + - No 5T4 at RT20
p5 ADT4 - - - - - - Poor quality at 2/3 time-
points
ADT12 - - - - - - Not Evaluable
RT20 +++ - ++ - - -
Very Poor Quality p10 ADT4 +++ ++ +++ + + + Poor quality at 2/3 time-
points
ADT12 - - - - - - Not Evaluable
RT20 + - - - - -
p6 ADT4 + - - - - - Poor quality at 3/3 time-
points
ADT12 ++ - - - - - Not Evaluable
RT20 - - - - - -Page 10 of 13
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Evaluating urine-mediated damage of exosomesFig re 6
Evaluating urine-mediated damage of exosomes. Exosomes coupled to microbeads were labelled with a luminal fluores-
cent dye (Calcein-AM), prior to incubation with various concentrations of NaCl (A) or with fresh urine specimens from four 
healthy donors (HD1-4) (B). In parallel, identical beads were set up, in the absence of Calcein-AM dye, stained instead with 
anti-MHC Class-I (RPE) conjugated antibody. After 1 h at room temperature, the fluorescence signal present in the FL-1 chan-
nel (Calcein) was compared to FL-2 fluorescence (Class-I-RPE). Graphs show ratio of Calcein to Class I fluorescence. To 
examine proteolytic damage of exosomes (C), western blot was performed for CD9, TSG101 and PSA on LNCaP-derived 
exosomes; which were incubated for 2 h or 18 h with fresh urine specimens (from three healthy donors), in the presence or 
absence of protease inhibitors. Trypsin was used as a positive control for proteolysis.
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Journal of Translational Medicine 2009, 7:4 http://www.translational-medicine.com/content/7/1/4by collection after prostate massage. Such modifications
together with improved methods for normalisation of the
sample (e.g. compare ratio of exosomes to urine creati-
nine for example as suggested [34]), should be adopted
for future studies. Regardless of these difficulties, the uri-
nary exosome compartment genuinely holds promise as
non-invasive source of tumour-associated antigens, for
PCa and likely other malignancies of the urological tract.
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